Virodhamine

The endocannabinoid with a split personality. Virodhamine is both agonist and antagonist at the cannabinoid CB1 receptor — full agonist at CB2 — an endogenous ligand that broke the family's tidy rules.

Neurotransmitter Class
Endocannabinoid (ester-linked arachidonate)
Receptors
CB1 (partial antagonist), CB2 (agonist)
Release Sites
Brain (hippocampus, striatum) and periphery
Clearance
FAAH and related hydrolases
Net Effect
CB1 brake on the cannabinoid tone; CB2 activation

Synthesis & Release

Virodhamine — arachidonic acid esterified with ethanolamine in the reverse orientation of anandamide (the name is anandamide reversed) — was identified in 2002 among endogenous cannabinoids. Brain concentrations rival anandamide in regions mapped by lipidomics's in some regions, suggesting a standing endogenous tone rather than pure on-demand bursts. FAAH-class enzymes clear it.

Receptor Actions

Physiological Role

Interactions

Clinical Relevance

Sources